These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 21327931)

  • 1. Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers.
    Shimoyama S
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):729-39. PubMed ID: 21327931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.
    Ramos FJ; Macarulla T; Capdevila J; Elez E; Tabernero J
    Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S52-7. PubMed ID: 19064407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy.
    Hendrickson AW; Haluska P
    Curr Opin Investig Drugs; 2009 Oct; 10(10):1032-40. PubMed ID: 19777391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug development for cancer chemoprevention: focus on molecular targets.
    Johnson KA; Brown PH
    Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of anti-epidermal growth factor receptor therapies with cytotoxic chemotherapy.
    Serrano C; Markman B; Tabernero J
    Cancer J; 2010; 16(3):226-34. PubMed ID: 20526101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to epidermal growth factor receptor-targeted therapy.
    Morgillo F; Lee HY
    Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma.
    Dempke WC; Heinemann V
    Anticancer Res; 2010 Nov; 30(11):4673-7. PubMed ID: 21115922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting apoptosis as an approach for gastrointestinal cancer therapy.
    Qiao L; Wong BC
    Drug Resist Updat; 2009 Jun; 12(3):55-64. PubMed ID: 19278896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours.
    Höpfner M; Baradari V; Huether A; Schöfl C; Scherübl H
    Endocr Relat Cancer; 2006 Mar; 13(1):135-49. PubMed ID: 16601284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting growth factors and angiogenesis; using small molecules in malignancy.
    Wanebo HJ; Argiris A; Bergsland E; Agarwala S; Rugo H
    Cancer Metastasis Rev; 2006 Jun; 25(2):279-92. PubMed ID: 16770540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era.
    Wagner AD; Moehler M
    Curr Opin Oncol; 2009 Jul; 21(4):381-5. PubMed ID: 19412098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The statins as anticancer agents.
    Chan KK; Oza AM; Siu LL
    Clin Cancer Res; 2003 Jan; 9(1):10-9. PubMed ID: 12538446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
    Feldkamp MM; Lau N; Guha A
    Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway.
    Kodach LL; Bleuming SA; Peppelenbosch MP; Hommes DW; van den Brink GR; Hardwick JC
    Gastroenterology; 2007 Oct; 133(4):1272-81. PubMed ID: 17919499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
    Baselga J; Arteaga CL
    J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor mutations in lung cancer.
    Sharma SV; Bell DW; Settleman J; Haber DA
    Nat Rev Cancer; 2007 Mar; 7(3):169-81. PubMed ID: 17318210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amplification of epidermal growth factor receptor gene but no evidence of ras mutations in primary human esophageal cancers.
    Hollstein MC; Smits AM; Galiana C; Yamasaki H; Bos JL; Mandard A; Partensky C; Montesano R
    Cancer Res; 1988 Sep; 48(18):5119-23. PubMed ID: 3044581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
    Dassonville O; Bozec A; Fischel JL; Milano G
    Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy.
    Morgillo F; Bareschino MA; Bianco R; Tortora G; Ciardiello F
    Differentiation; 2007 Nov; 75(9):788-99. PubMed ID: 17608727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.